Gastrointestinal non-systemic virus disinfection as a new paradigm and a new modality for successful prevention, prophylaxis, and therapy to SARS-Cov-2 and Covid-19
Создано на: 2021.11.09
Gastrointestinal non-systemic virus disinfection as a new paradigm and a new modality for successful prevention, prophylaxis, and therapy to SARS-Cov-2 and Covid-19
Executive summary:
1. Vaccination is the key element to overcome SARS-CoV-2 pandemic, however vaccination alone, results no full control over pandemic. New waves, with new infections, re-infections, post-covid virus latency happen. Therefore, new paradigm, new treatment modalities shall be developed, deployed.
2. Vaccination have mostly systemic effect, therefore virus may also be present in the GI tract of asymptomatic carriers and of Covid-19 patients, too.
3. Successful repurposing of drugs with well-established use (WEU) is the quickest, safest route of development of medicines with new indication.
4. R&D professionals of PannonPharma have identified an strong antiviral agent against SARS-CoV-2, which may apply in GI tracts due to its non-systemic effect.
5. This repurposed (WEU) drug has a double action, in its GI tract disinfection mechanism, and it is code named, as CovGiDi (Corona virus disinfection).
6. It is a safe and efficient, non-systemic, mainly gastrointestinal antibiotic agent, acting against coronaviruses, including all their recent, present and future mutants, as well.
7. Prevention / prophylaxis with CovGIDI ought be done already at early gastric symptoms of SARS-CoV-2 infection (discomfort, pain, nausea, vomiting, diarrhoea etc.).
8. Prompt action in SARS-CoV-2 pandemic might be possible with Temporary Emergency Marketing Authorization.
9. We are looking for the opportunities to cooperate with pharmaceutical industry, universities, governmental control/ regulatory authorities.